Muscular Dystrophy and cannabis in Oklahoma
The state does not list this condition by name, but its statute or regulator permits a certifying physician to add conditions case-by-case. Patients should expect to bring full diagnostic records to the certification visit.
- ✗ No
- LEGAL
- 3 oz on person; 8 oz at…
- POSSESSION
- $100/yr
- STATE FEE
- 7–21 d
- TIMELINE
Oklahoma statute and program
The Oklahoma Medical Marijuana Program is the operating authority for Oklahoma patient certification. The authoritative legal text is: Title 63 OK Stat. §§ 420 et seq.: Oklahoma Medical Marijuana Authority Act.
What the evidence says about cannabis and Muscular Dystrophy
Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.
How to qualify in Oklahoma
The Oklahoma Medical Marijuana Program requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):
- Get a written recommendation from any Oklahoma-licensed physician. Under State Question 788 (codified at 63 O.S. §420 et seq.), any Oklahoma-licensed MD or DO may issue a written recommendation for medical cannabis. The Oklahoma program is the broadest practitioner-discretion model in the United States — there is no enumerated qualifying-condition list. The physician determines that medical cannabis is appropriate for the patient using "the same accepted standards a reasonable and prudent physician would follow."
- Apply through the OMMA online portal. The patient creates an account on the Oklahoma Medical Marijuana Authority (OMMA) online portal, uploads the physician recommendation, a current Oklahoma driver license or state ID, a passport-style photo, and proof of Oklahoma residency. Two-year licenses are now standard since 2023 OMMA rule revisions.
- Pay the $100 state fee (or $20 for SoonerCare/Medicaid). The two-year Oklahoma medical marijuana patient license fee is $100, reduced to $20 for patients enrolled in SoonerCare (Oklahoma Medicaid) or Medicare. Caregivers register separately and pass a state background check. Fees are paid online during the OMMA application submission.
- Receive the license and purchase from any OMMA-licensed dispensary. OMMA patient licenses are typically issued within 14 days of complete application; expedited processing is available. Oklahoma allows possession of 3 ounces on the person, 8 ounces at home, 1 ounce of concentrate, 72 ounces of edibles, and 6 mature plus 6 seedling plants. Oklahoma honors out-of-state medical cards under its 30-day temporary license program ($100 application fee) and has the highest per-capita patient enrollment of any US state.
- State registration fee
- $100
- Physician visit (typical)
- $50–$150
- Certification to card
- 7–21 days
- Out-of-state patients
- Eligible
- Minors
- Eligible with caregiver
For full Oklahoma registration steps, fees, and reciprocity rules, see the Oklahoma cannabis-laws page.
ICD-10 code
A certifying physician documenting Muscular Dystrophy for the Oklahoma medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Oklahoma list Muscular Dystrophy as a qualifying condition for medical cannabis?
Not by name, but Oklahoma permits physician discretion. Under Oklahoma Medical Marijuana Program, a certifying physician can add a condition like Muscular Dystrophy on a case-by-case basis when the physician judges that the patient would benefit from medical cannabis. This is different from a state where the qualifying-condition list is fixed in statute. Whether a particular physician will certify Muscular Dystrophy depends on the physician's training, the strength of the patient's documentation, and the practitioner's reading of the available evidence — evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). Patients should expect to bring full diagnostic records to the certification visit.
How do I get a Oklahoma medical marijuana card for Muscular Dystrophy?
Step one is finding a physician licensed in Oklahoma who is registered with Oklahoma Medical Marijuana Program and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Oklahoma honors out-of-state medical cards under its reciprocity rules — uncommon, and worth verifying before relying on it. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.
What does the evidence say about cannabis for Muscular Dystrophy?
For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Title 63 OK Stat. §§ 420 et seq.: Oklahoma Medical Marijuana Authority Actaccessed May 16, 2026
- Oklahoma Medical Marijuana Authorityaccessed May 16, 2026
- Wikipedia: Cannabis in Oklahomaaccessed May 16, 2026
- OMMA: Patient Application Fees and Processaccessed May 18, 2026
- OMMA: Out-of-State (Temporary) Patient Licenseaccessed May 18, 2026
- Oklahoma Legislature bill trackeraccessed May 18, 2026
- NORML: Oklahoma Laws & Penaltiesaccessed May 18, 2026
- National Academies of Sciences, Engineering, and Medicine (2017): The Health Effects of Cannabis and Cannabinoidsaccessed May 18, 2026
- NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
- Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
- MedlinePlus: Muscular dystrophyaccessed May 18, 2026
- FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026